indicated that the benefit of gemcitabine combination chemotherapy is predominantly seen in patients with good PS. 51 – 53 Gemcitabine Plus Albumin-Bound Paclitaxel: Albumin-bound paclitaxel is a nanoparticle form of paclitaxel. In a phase I/II trial, 67
Search Results
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow
Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Presented by: Joyce F. Liu
with different clinical and genomic characteristics, which may influence response to treatments beyond the standard carboplatin/paclitaxel regimen. Genetic testing of newly diagnosed patients not only informs patient care but also prompts cascade
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Farhood Farjah, Hans Gerdes, Michael Gibson, Patrick Grierson, Wayne L. Hofstetter, David H. Ilson, Shadia Jalal, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel Klempner, Jill Lacy, Frank Licciardi, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Aaron Miller, Sarbajit Mukherjee, Mary F. Mulcahy, Darryl Outlaw, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole R. McMillian, and Lenora A. Pluchino
options to the standard DCF regimen for first-line therapy. Additional regimens for first-line therapy include paclitaxel with either carboplatin or cisplatin, 121 – 123 docetaxel with cisplatin, 115 , 124 or single-agent fluoropyrimidine (fluorouracil
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes
intravenous paclitaxel/carboplatin or docetaxel/carboplatin. 143 Fertility-sparing surgery and/or observation/monitoring are options for patients with unilateral clear cell borderline tumors (see LCOH-6; page 1141). For patients with stage II to IV clear cell
Stereotactic Body Radiation Therapy: A New Standard Option for Pancreatic Cancer?
Joseph M. Herman and Albert C. Koong
cancer. In addition, multiagent chemotherapy regimens such as FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin) and gemcitabine with nab-paclitaxel have resulted in significant improvements in survival when compared to gemcitabine monotherapy
Biomarker-Based Treatment Selection in Non–Small Cell Lung Cancer
Wallace Akerley
gefitinib (an EGFR inhibitor) versus carboplatin/paclitaxel ( P <.001), whereas those who were EGFR -negative had significantly improved PFS on carboplatin/paclitaxel versus gefitinib ( P <.001). 2 “This early study showed that PFS was significantly
In Chemotherapy for Lung Cancer, Sometimes Less is More
Eric Roeland, Charles Loprinzi, Timothy J. Moynihan, Thomas J. Smith, and Jennifer Temel
cytotoxic agents in patients in similar settings: 2 months for bevacizumab when added to carboplatin/paclitaxel and 2.6 months for maintenance pemetrexed. 17 , 18 Although the possibility of prolonged survival with supportive care interventions has been
Ten Years of Progress in Non–Small Cell Lung Cancer
David S. Ettinger
empiric, usually a platinum-based doublet. However in 2006, the FDA approved use of the anti-vascular endothelial growth factor monoclonal antibody, bevacizumab, with paclitaxel and carboplatin (PCB). This approval was based on the results of the ECOG
Supportive Care in Head and Neck Cancers: Multidisciplinary Management
Presented by: Jimmy J. Caudell, David G. Pfister, and Randal S. Weber
chemotherapy (as was the standard at the time) with carboplatin and paclitaxel for 2 cycles. According to Dr. Caudell, this patient did well for years, but in 2019 presented with perceived slurring of speech. On examination, his tongue deviated to the right
The Role of Inhibitors of the Epidermal Growth Factor in Management of Head and Neck Cancer
Bruce Brockstein, Mario Lacouture, and Mark Agulnik
Edited by Kerrin G. Robinson
. Hitt R Irigoyen A Nunez J . Phase II study of combination cetuximab plus weekly paclitaxel in patients with recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN) [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): Abstract 6012